BioRock Ventures

Profile

BioRock Ventures is a seed venture capital fund based in the Bay Area, California. The firm is led by Mary Wheeler, a Kauffman Fellow and founding managing partner with extensive experience in therapeutics startups and major pharmaceuticals roles, including strategic positions at Johnson & Johnson and Allergan. BioRock Ventures is distinguished by its deep expertise in the life sciences sector, particularly in therapeutics, and its emphasis on seed to pre-IPO investments across various therapeutic modalities.

The firm focuses on seed-sized investments into life science companies developing novel FDA-regulated therapeutic drugs. BioRock Ventures invests in all disease areas and stages, from angel and seed to Series A through pre-IPO/M&A. The geographic focus encompasses primarily North America, with a specialized focus on therapeutics innovation. The firm currently manages two funds: Fund I and Fund II, concentrating on seeding next-generation therapeutics.

Notable investments from BioRock Ventures include Immusoft - a company focused on engineered B cell therapies, AN2 Therapeutics - known for its novel small molecule therapeutics, Primmune Therapeutics - specializing in immune system therapies, PTM Therapeutics, and Vaxcyte. These investments underscore the firm’s strategic focus on therapeutics with significant potential for clinical advancement and regulatory approval.